KBA-1412

N/A

Report date: 2023/12/21 17:56:02

Base Information

Drug NameKBA-1412
Drug Alias NameKBA-1412KBA1412AT-1412
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-CD9 antigen
TargetsCD9 antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumNetherlands
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAimm Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesKling Biotherapeutics BV
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A